Anumana named in Fierce Medtech's Fierce 15 for 2022

See Article

Diagnostic Algorithm Pipeline

Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.

divider
Program
Development
Pre-Submission
Validation
Submission
Market Authorization
Low Ejection Fraction
Novartis

Granted FDA Breakthrough Device Designation

Phase: Validation

Pulmonary Hypertension
Janssen

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Hyperkalemia

Granted FDA Breakthrough Device Designation

Phase: Development

Cardiac Amyloidosis
Pfizer

Phase: Pre-Submission

Atrial Fibrillation in Normal Sinus Rhythm

Phase: Pre-Submission

Hypertrophic Cardiomyopathy

Phase: Development

Myocarditis

Phase: Development

Aortic Stenosis

Phase: Development

Early Stage Development Programs

Phase: Development

Interventional EP Product Pipeline

Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.

Program
Development
Pre-Submission
Validation
Submission
Authorization
Hardware Agnostic AI/ML-based EAM Software

Phase: Submission

EP Case Review Software

FDA Clearance Not Required

Phase: Validation

Signal Identification Software

Phase: Validation

Early Stage Development Programs

Phase: Development

Download Our One-Pager

Featuring key corporate highlights and an overview of Anumana's technology